Skip to main content

Peer Review reports

From: Targeting integrated stress response with ISRIB combined with imatinib treatment attenuates RAS/RAF/MAPK and STAT5 signaling and eradicates chronic myeloid leukemia cells

Original Submission
24 Jul 2022 Submitted Original manuscript
19 Aug 2022 Reviewed Reviewer Report
25 Aug 2022 Reviewed Reviewer Report
5 Oct 2022 Author responded Author comments - Katarzyna Piwocka
Resubmission - Version 2
5 Oct 2022 Submitted Manuscript version 2
13 Oct 2022 Author responded Author comments - Katarzyna Piwocka
Resubmission - Version 3
13 Oct 2022 Submitted Manuscript version 3
13 Oct 2022 Author responded Author comments - Katarzyna Piwocka
Resubmission - Version 4
13 Oct 2022 Submitted Manuscript version 4
17 Oct 2022 Author responded Author comments - Katarzyna Piwocka
Resubmission - Version 5
17 Oct 2022 Submitted Manuscript version 5
31 Oct 2022 Reviewed Reviewer Report
2 Nov 2022 Reviewed Reviewer Report
Resubmission - Version 6
Submitted Manuscript version 6
Publishing
7 Nov 2022 Editorially accepted
2 Dec 2022 Article published 10.1186/s12885-022-10289-w

You can find further information about peer review here.

Back to article page